Moderna closed yesterday at $196.79, down nearly 5% on the session. That places it roughly 30% below its 2026 high of $280.80. The stock has fallen from above $258 to $196 in two weeks on no negative clinical news. For a company that began 2026 trading near $31 and is still up over 500% for the year, this pullback demands a clear-eyed look at both sides.
Why This Stock Now
Moderna stock traded at $174.93 on August 20, 2026, up from $62.96 two sessions earlier, after Moderna and Merck’s mRNA cancer vaccine cleared a Phase 3 melanoma trial. That single event launched the rally. Everything that followed, including a Q3 earnings beat, Nasdaq-100 inclusion, and raised revenue guidance, built on that one result. The stock is now retracing while the company advances toward the American Society of Hematology meeting, where additional mRNA-2808 data in blood cancers is expected.
The Business
Moderna’s commercial base remains vaccines. In Q3 2026, the company reported revenue of $1.3 billion, GAAP net income of $0.2 billion, and increased its 2026 expected revenue growth to 15% to 25%, while also highlighting U.S. FDA approval of mFLUSIVA, its fourth approved product in the United States. Moderna said it still expects approximately half of its 2026 revenue to come from the United States and half from international markets. The company swung from a $0.51-per-share loss one year earlier to a $0.38 profit.
The commercial vaccine portfolio funds the pipeline. The company is advancing intismeran in collaboration with Merck, with multiple Phase 2 and Phase 3 clinical trials underway across multiple tumor types. Moderna and Merck have reported Phase 3 data showing intismeran in combination with Keytruda reduced the risk of recurrence or death by 42% compared to Keytruda alone in the intent-to-treat population, and by 49% in a prespecified modified intent-to-treat sensitivity analysis.
Why Wall Street Is Paying Attention
Moderna raised its full-year 2026 revenue growth guidance to 15% to 25%, up from previous expectations of up to 10% growth. The company strengthened its balance sheet with about $8 billion in cash and investments, aided by a $3 billion convertible debt financing that carries a 0.00% coupon. Management also cut the 2026 R&D budget by $200 million, lowering it to $2.7 billion, as more studies wind down.
Moderna was dropped from the Nasdaq-100 in late 2024 and has re-entered after the sharp recovery in its share price, with MRNA shares gaining massively after the company announced late-stage trial results of its cancer vaccine in combination with Merck’s Keytruda in August.
What’s Driving the Opportunity
The pullback has created a more rational entry than existed at $280 in September or $246 in October. Upcoming ASH data for the mRNA-2808 blood cancer program is expected to include more patients and longer follow-up versus the initial response data, and to evaluate activity in patients with prior BCMA- and GPRC5D-targeted treatment. If those data are consistent with the melanoma result, the platform argument gains a second oncology leg and a material new addressable market.
Over the past twelve months, the stock returned 978.9%, compared with 9.8% for the S&P 500. The current price, 30% below the peak, represents a company with a proven Phase 3 melanoma result, a funded balance sheet, and multiple approved commercial products. That is a meaningfully different company than the one trading near $31 in early January.
What Could Go Wrong
The valuation disconnect is severe and cannot be dismissed. JPMorgan raised its price target on Moderna to $102 from $77 while maintaining an Underweight rating. Intismeran is not approved to treat a single cancer, and the stock appears priced as if it will treat several. The norovirus vaccine program did not meet statistical criteria for early success in Phase 3, and the company has said it decided not to enroll an additional cohort this coming winter season.
The path has not run one way: the stretch to current levels included the largest one-day move of the year, a 177% jump on August 19, followed by a 24% fall the next day. This is a stock that moves 10% or more in a single session on a regular basis. That volatility is the cost of admission.
The Bottom Line
Moderna is the highest-risk, highest-reward idea in this issue. The year-to-date gain has compressed considerably from its peak, and the next material clinical data point has not yet arrived. For investors with appropriate risk tolerance, the current level represents a more considered entry than existed at the September high. The cancer vaccine story is real and supported by Phase 3 data. What the approval timeline looks like, and what the commercial opportunity ultimately delivers, remains genuinely uncertain. That uncertainty is precisely why the stock is 30% off its high.
